FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016324269> ?p ?o ?g. }

• W2016324269 endingPage "1034" @default.
• W2016324269 startingPage "1027" @default.
• W2016324269 abstract "Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy.BackgroundConversion from cyclosporine to azathioprine after renal transplantation has been shown to be beneficial in terms of allograft function, cardiovascular risk factor profile, and the incidence of gout. A higher incidence of acute rejection, however, has also been reported and uncertainty still exists about the long-term outcome after conversion. We report on the extended follow-up of an open-label, randomized trial that examined conversion to azathioprine as early as three months after transplantation.MethodsOne hundred twenty-eight patients were enrolled in this single-center study. Three months after transplantation they were randomly assigned to continue cyclosporine treatment (N = 68), or they were converted to azathioprine (N = 60). The steroid dose was temporarily increased in the patients who were converted.ResultsPatient survival was not different in the two groups. Graft survival tended to be lower (64.7% vs. 76.5% at 15 years) in the cyclosporine continuation group (P = 0.14) when data were analyzed on an intention to treat basis. The graft survival of the patients that stayed on their assigned treatment was significantly higher in the azathioprine arm, starting at two years' post-transplantation. The glomerular filtration rate was significantly higher in the patients who were converted to azathioprine. More allograft biopsies were taken from patients remaining on cyclosporine for suspicion of cyclosporine-related nephrotoxicity and prompted a high rate of late conversions (19%). The relative risk of chronic allograft nephropathy was significantly higher in the group that continued cyclosporine [relative risk, 4.3 (95% CI, 1.4 to 12.9); P = 0.009]. Conversion to azathioprine reduced the need of blood pressure and lipid-lowering drugs.ConclusionConversion to a calcineurin inhibitor–free immunosuppressive regiment three months after renal transplantation improved allograft function, reduced the need of cardiovascular risk factor–controlling medication, and reduced the incidence of chronic allograft nephropathy. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Conversion from cyclosporine to azathioprine after renal transplantation has been shown to be beneficial in terms of allograft function, cardiovascular risk factor profile, and the incidence of gout. A higher incidence of acute rejection, however, has also been reported and uncertainty still exists about the long-term outcome after conversion. We report on the extended follow-up of an open-label, randomized trial that examined conversion to azathioprine as early as three months after transplantation. One hundred twenty-eight patients were enrolled in this single-center study. Three months after transplantation they were randomly assigned to continue cyclosporine treatment (N = 68), or they were converted to azathioprine (N = 60). The steroid dose was temporarily increased in the patients who were converted. Patient survival was not different in the two groups. Graft survival tended to be lower (64.7% vs. 76.5% at 15 years) in the cyclosporine continuation group (P = 0.14) when data were analyzed on an intention to treat basis. The graft survival of the patients that stayed on their assigned treatment was significantly higher in the azathioprine arm, starting at two years' post-transplantation. The glomerular filtration rate was significantly higher in the patients who were converted to azathioprine. More allograft biopsies were taken from patients remaining on cyclosporine for suspicion of cyclosporine-related nephrotoxicity and prompted a high rate of late conversions (19%). The relative risk of chronic allograft nephropathy was significantly higher in the group that continued cyclosporine [relative risk, 4.3 (95% CI, 1.4 to 12.9); P = 0.009]. Conversion to azathioprine reduced the need of blood pressure and lipid-lowering drugs. Conversion to a calcineurin inhibitor–free immunosuppressive regiment three months after renal transplantation improved allograft function, reduced the need of cardiovascular risk factor–controlling medication, and reduced the incidence of chronic allograft nephropathy." @default.
• W2016324269 created "2016-06-24" @default.
• W2016324269 creator A5021917052 @default.
• W2016324269 creator A5029821903 @default.
• W2016324269 creator A5044239106 @default.
• W2016324269 creator A5058384202 @default.
• W2016324269 creator A5069808607 @default.
• W2016324269 creator A5089060945 @default.
• W2016324269 date "2003-09-01" @default.
• W2016324269 modified "2023-10-17" @default.
• W2016324269 title "Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy" @default.
• W2016324269 cites W1906296259 @default.
• W2016324269 cites W1923079464 @default.
• W2016324269 cites W1974594385 @default.
• W2016324269 cites W1979155203 @default.
• W2016324269 cites W1980113811 @default.
• W2016324269 cites W1988037390 @default.
• W2016324269 cites W1995139644 @default.
• W2016324269 cites W1995791071 @default.
• W2016324269 cites W1998289175 @default.
• W2016324269 cites W2002514824 @default.
• W2016324269 cites W2003655983 @default.
• W2016324269 cites W2018523148 @default.
• W2016324269 cites W2027751794 @default.
• W2016324269 cites W2031569062 @default.
• W2016324269 cites W2041875841 @default.
• W2016324269 cites W2051143996 @default.
• W2016324269 cites W2051891058 @default.
• W2016324269 cites W2083046874 @default.
• W2016324269 cites W2103607869 @default.
• W2016324269 cites W2103973749 @default.
• W2016324269 cites W2110207772 @default.
• W2016324269 cites W2123036912 @default.
• W2016324269 cites W2131290131 @default.
• W2016324269 cites W2142388081 @default.
• W2016324269 cites W3021452643 @default.
• W2016324269 doi "https://doi.org/10.1046/j.1523-1755.2003.00175.x" @default.
• W2016324269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12911553" @default.
• W2016324269 hasPublicationYear "2003" @default.
• W2016324269 type Work @default.
• W2016324269 sameAs 2016324269 @default.
• W2016324269 citedByCount "53" @default.
• W2016324269 countsByYear W20163242692012 @default.
• W2016324269 countsByYear W20163242692013 @default.
• W2016324269 countsByYear W20163242692014 @default.
• W2016324269 countsByYear W20163242692015 @default.
• W2016324269 countsByYear W20163242692016 @default.
• W2016324269 countsByYear W20163242692017 @default.
• W2016324269 countsByYear W20163242692021 @default.
• W2016324269 countsByYear W20163242692023 @default.
• W2016324269 crossrefType "journal-article" @default.
• W2016324269 hasAuthorship W2016324269A5021917052 @default.
• W2016324269 hasAuthorship W2016324269A5029821903 @default.
• W2016324269 hasAuthorship W2016324269A5044239106 @default.
• W2016324269 hasAuthorship W2016324269A5058384202 @default.
• W2016324269 hasAuthorship W2016324269A5069808607 @default.
• W2016324269 hasAuthorship W2016324269A5089060945 @default.
• W2016324269 hasBestOaLocation W20163242691 @default.
• W2016324269 hasConcept C120665830 @default.
• W2016324269 hasConcept C121332964 @default.
• W2016324269 hasConcept C126189478 @default.
• W2016324269 hasConcept C126322002 @default.
• W2016324269 hasConcept C126894567 @default.
• W2016324269 hasConcept C134018914 @default.
• W2016324269 hasConcept C141071460 @default.
• W2016324269 hasConcept C159641895 @default.
• W2016324269 hasConcept C2776760755 @default.
• W2016324269 hasConcept C2779134260 @default.
• W2016324269 hasConcept C2779458710 @default.
• W2016324269 hasConcept C2779528694 @default.
• W2016324269 hasConcept C2780091579 @default.
• W2016324269 hasConcept C2780303639 @default.
• W2016324269 hasConcept C2781184683 @default.
• W2016324269 hasConcept C2911091166 @default.
• W2016324269 hasConcept C555293320 @default.
• W2016324269 hasConcept C61511704 @default.
• W2016324269 hasConcept C71924100 @default.
• W2016324269 hasConcept C90924648 @default.
• W2016324269 hasConceptScore W2016324269C120665830 @default.
• W2016324269 hasConceptScore W2016324269C121332964 @default.
• W2016324269 hasConceptScore W2016324269C126189478 @default.
• W2016324269 hasConceptScore W2016324269C126322002 @default.
• W2016324269 hasConceptScore W2016324269C126894567 @default.
• W2016324269 hasConceptScore W2016324269C134018914 @default.
• W2016324269 hasConceptScore W2016324269C141071460 @default.
• W2016324269 hasConceptScore W2016324269C159641895 @default.
• W2016324269 hasConceptScore W2016324269C2776760755 @default.
• W2016324269 hasConceptScore W2016324269C2779134260 @default.
• W2016324269 hasConceptScore W2016324269C2779458710 @default.
• W2016324269 hasConceptScore W2016324269C2779528694 @default.
• W2016324269 hasConceptScore W2016324269C2780091579 @default.
• W2016324269 hasConceptScore W2016324269C2780303639 @default.
• W2016324269 hasConceptScore W2016324269C2781184683 @default.
• W2016324269 hasConceptScore W2016324269C2911091166 @default.
• W2016324269 hasConceptScore W2016324269C555293320 @default.
• W2016324269 hasConceptScore W2016324269C61511704 @default.
• W2016324269 hasConceptScore W2016324269C71924100 @default.
• W2016324269 hasConceptScore W2016324269C90924648 @default.

• next